Citadel Advisors
HOWL icon

Citadel Advisors’s Werewolf Therapeutics HOWL Stock Holding History

Citadel Advisors’s Portfolio HOWL Stock Details HOWL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.58K Buy
+15,500
New +$9.44K ﹤0.01% 13533
2025
Q2 		– Sell
-13,600
Closed -$13.2K – 13595
2025
Q1 		$13.2K Sell
13,600
-400
-3% -$524 ﹤0.01% 13409
2024
Q4 		$20.7K Buy
14,000
+13,500
+2,700% +$27.5K ﹤0.01% 13164
2024
Q3 		$1.06K Sell
500
-800
-62% -$1.82K ﹤0.01% 13910
2024
Q2 		$3.17K Sell
1,300
-6,000
-82% -$28.8K ﹤0.01% 13618
2024
Q1 		$47.3K Buy
7,300
+7,200
+7,200% +$42K ﹤0.01% 12222
2023
Q4 		$386 Buy
+100
New +$255 ﹤0.01% 14047

Other funds holding HOWL

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
DF
DC Funds Mclean, Virginia $1.25M AUM 26.51% 1-Year Est. Return
VA
Verdad Advisers Boston, Massachusetts $104M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Citadel Advisors's HOWL Position: Q2 2026 in Review

Citadel Advisors sold out of Werewolf Therapeutics (HOWL) in Q2 2026, closing a stake of 10,382 shares — an estimated $6.33K sold.

Citadel Advisors first reported a position in HOWL in Q1 2022 and held it in 8 quarters. The position peaked at $304K in Q3 2025. 45 funds tracked by Wall St. Rank hold HOWL as of Q2 2026.

  • Citadel Advisors reported no remaining Werewolf Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Citadel Advisors sold 10,382 Werewolf Therapeutics shares in Q2 2026, an estimated $6.33K.
  • Citadel Advisors first reported a position in Werewolf Therapeutics in Q1 2022 and held it in 8 quarters.
  • Citadel Advisors's Werewolf Therapeutics position peaked at $304K in Q3 2025.
  • 45 funds tracked by Wall St. Rank held Werewolf Therapeutics as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.